drugset / Trial / NCT04095390
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of pyrotinib combination with CDK4/6 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2021-11-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 500 mg | — |
| Subject | Dalpiciclib | Small molecule | 125 mg | — |
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Pyrotinib | Small molecule | 400 mg | — |